Abstract
The MLL gene at chromosome 11q23 is frequently rearranged in acute leukemia. Here we report the identification of a new MLL fusion partner in the case of an infant with AML-M4 and a t(11;17)(q23;q21) translocation. Fluorescence in situ hybridization (FISH) and RT-PCR analyses indicated a rearrangement of the MLL gene, but no fusion with previously identified MLL fusion partners at 17q, such as AF17 or MSF. Rapid amplification of cDNA ends (RACE) revealed an in-frame fusion of MLL to LASP1, a gene that is amplified and overexpressed in breast cancer. Retroviral transduction of myeloid progenitors demonstrated that MLL/LASP1 is the fourth known fusion of MLL with a cytoplasmic protein that has no in vitro transformation capability, thus establishing a potential subgroup among the MLL fusion proteins.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ayton PM and Cleary ML. (2001). Oncogene, 20, 5695–5707.
Borkhardt A, Teigler-Schlegel A, Fuchs U, Keller C, Konig M, Harbott J and Haas OA. (2001). Genes Chromosomes Cancer, 32, 82–88.
Butler LH, Slany R, Cui X, Cleary ML and Mason DY. (1997). Blood, 89, 3361–3370.
Chew CS, Parente Jr JA, Chen X, Chaponnier C and Cameron RS. (2000). J. Cell Sci., 113, 2035–2045.
Chew CS, Parente Jr JA, Zhou C, Baranco E and Chen X. (1998). Am. J. Physiol., 275, 56–67.
Daheron L, Veinstein A, Brizard F, Drabkin H, Lacotte L, Guilhot F, Larsen CJ, Brizard A and Roche J. (2001). Genes Chromosomes Cancer, 31, 382–389.
DiMartino JF, Ayton PM, Chen EH, Naftzger CC, Young BD and Cleary ML. (2002). Blood, 99, 3780–3785.
DiMartino JF and Cleary ML. (1999). Br. J. Haematol., 106, 614–626.
Ernst P, Wang J and Korsmeyer SJ. (2002). Curr. Opin. Hematol., 9, 282–287.
Felix CA and Lange BJ. (1999). Oncologist, 4, 225–240.
Fuchs U, Rehkamp G, Haas OA, Slany R, Konig M, Bojesen S, Bohle RM, Damm-Welk C, Ludwig WD, Harbott J and Borkhardt A. (2001). Proc. Natl. Acad. Sci. USA, 98, 8756–8761.
Greil J, Gramatzki M, Burger R, Marschalek R, Peltner M, Trautmann U, Hansen-Hagge TE, Bartram CR, Fey GH, Stehr K and Beck J. (1994). Br. J. Haematol., 86, 275–283.
Huret JL. (2001). URL: http://www.infobiogen.fr/services/chromcancer/Anomal.
Huret JL, Dessen P and Bernheim A. (2001). Leukemia, 15, 987–989.
Lavau C, Du C, Thirman M and Zeleznik-Le N. (2000a). EMBO J., 19, 4655–4664.
Lavau C, Luo RT, Du C and Thirman MJ. (2000b). Proc. Natl. Acad. Sci. USA, 97, 10984–10989.
Lavau C, Szilvassy SJ, Slany R and Cleary ML. (1997). EMBO J., 16, 4226–4237.
Megonigal MD, Cheung NK, Rappaport EF, Nowell PC, Wilson RB, Jones DH, Addya K, Leonard DG, Kushner BH, Williams TM, Lange BJ and Felix CA. (2000). Proc. Natl. Acad. Sci. USA, 97, 2814–2819.
Osaka M, Rowley JD and Zeleznik-Le NJ. (1999). Proc. Natl. Acad. Sci. USA, 96, 6428–6433.
Prasad R, Leshkowitz D, Gu Y, Alder H, Nakamura T, Saito H, Huebner K, Berger R, Croce CM and Canaani E. (1994). Proc. Natl. Acad. Sci. USA, 91, 8107–8111.
Rowley JD. (1999). Semin. Hematol., 36, 59–72.
Schreiber V, Masson R, Linares JL, Mattei MG, Tomasetto C and Rio MC. (1998a). Gene, 207, 171–175.
Schreiber V, Moog-Lutz C, Regnier CH, Chenard MP, Boeuf H, Vonesch JL, Tomasetto C and Rio MC. (1998b). Mol. Med., 4, 675–687.
Slany RK, Lavau C and Cleary ML. (1998). Mol. Cell Biol., 18, 122–129.
Taki T, Ohnishi H, Shinohara K, Sako M, Bessho F, Yanagisawa M and Hayashi Y. (1999). Cancer Res., 59, 4261–4265.
Tomasetto C, Moog-Lutz C, Regnier CH, Schreiber V, Basset P and Rio MC. (1995a). FEBS Lett., 373, 245–249.
Tomasetto C, Regnier C, Moog-Lutz C, Mattei MG, Chenard MP, Lidereau R, Basset P and Rio MC. (1995b). Genomics, 28, 367–376.
von Bergh A, Emanuel B, van Zelderen-Bhola S, Smetsers T, van Soest R, Stul M, Vranckx H, Schuuring E, Hagemeijer A and Kluin P. (2000). Genes Chromosomes Cancer, 28, 14–22.
Acknowledgements
This study was supported by the ‘Österreichische Kinderkrebshilfe’ and the German Cancer Foundation with a grant to AB (10-1658-Bo) and by DFG grants (SL27/4-1, SFB466/C7, SFB473/B10) to RS. This work resulted from a cooperation within the framework of the international BFM Study Group.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Strehl, S., Borkhardt, A., Slany, R. et al. The human LASP1 gene is fused to MLL in an acute myeloid leukemia with t(11;17)(q23;q21). Oncogene 22, 157–160 (2003). https://doi.org/10.1038/sj.onc.1206042
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206042
Keywords
This article is cited by
-
From initiation to eradication: the lifespan of an MLL-rearranged therapy-related paediatric AML
Bone Marrow Transplantation (2015)
-
Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localisation
British Journal of Cancer (2007)
-
Complex MLL rearrangements in t(4;11) leukemia patients with absent AF4 · MLL fusion allele
Leukemia (2007)
-
SEPT2 is a new fusion partner of MLL in acute myeloid leukemia with t(2;11)(q37;q23)
Oncogene (2006)
-
ArgBP2, encoding a negative regulator of ABL, is fused to MLL in a case of infant M5 acute myeloid leukemia involving 4q35 and 11q23
Leukemia (2006)